Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Net Margin (2017 - 2025)

Sutro Biopharma's Net Margin history spans 9 years, with the latest figure at 507.54% for Q3 2025.

  • For Q3 2025, Net Margin rose 6508.0% year-over-year to 507.54%; the TTM value through Sep 2025 reached 192.12%, down 11113.0%, while the annual FY2024 figure was 366.62%, 29715.0% down from the prior year.
  • Net Margin for Q3 2025 was 507.54% at Sutro Biopharma, down from 15.27% in the prior quarter.
  • Across five years, Net Margin topped out at 27.31% in Q4 2023 and bottomed at 1224.79% in Q1 2025.
  • The 5-year median for Net Margin is 370.0% (2023), against an average of 353.63%.
  • The largest annual shift saw Net Margin soared 42807bps in 2023 before it plummeted -77727bps in 2025.
  • A 5-year view of Net Margin shows it stood at 357.85% in 2021, then decreased by -12bps to 400.76% in 2022, then skyrocketed by 107bps to 27.31% in 2023, then crashed by -1891bps to 489.18% in 2024, then dropped by -4bps to 507.54% in 2025.
  • Per Business Quant, the three most recent readings for STRO's Net Margin are 507.54% (Q3 2025), 15.27% (Q2 2025), and 1224.79% (Q1 2025).